Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study-Reference-Cited by-同舟云学术

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Published:2022-04-08 Issue:4 Volume:76 Page:1000-1012
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

D’Alessio Antonio¹²^ORCID,Fulgenzi Claudia Angela Maria¹³,Nishida Naoshi⁴,Schönlein Martin⁵^ORCID,von Felden Johann⁶,Schulze Kornelius⁶,Wege Henning⁶,Gaillard Vincent E.⁷,Saeed Anwaar⁸,Wietharn Brooke⁸,Hildebrand Hannah⁸,Wu Linda⁹,Ang Celina⁹,Marron Thomas U.⁹,Weinmann Arndt¹⁰,Galle Peter R.¹⁰,Bettinger Dominik¹¹^ORCID,Bengsch Bertram¹¹¹²¹³,Vogel Arndt¹⁴,Balcar Lorenz¹⁵,Scheiner Bernhard¹⁵^ORCID,Lee Pei‐Chang¹⁶,Huang Yi‐Hsiang¹⁶¹⁷^ORCID,Amara Suneetha¹⁸,Muzaffar Mahvish¹⁸,Naqash Abdul Rafeh¹⁸¹⁹,Cammarota Antonella²²⁰,Personeni Nicola²²⁰,Pressiani Tiziana²⁰,Sharma Rohini¹,Pinter Matthias¹⁵^ORCID,Cortellini Alessio¹,Kudo Masatoshi⁴,Rimassa Lorenza²²⁰,Pinato David J.¹²¹

Affiliation:

1. Department of Surgery & Cancer Imperial College London Hammersmith Hospital London UK

2. Department of Biomedical Sciences Humanitas University Pieve Emanuele, Milan Italy

3. Division of Medical Oncology Policlinico Universitario Campus Bio‐Medico Rome Italy

4. Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

5. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Center Hamburg‐Eppendorf Hamburg Germany

6. Department of Medicine University Medical Center Hamburg‐Eppendorf Hamburg Germany

7. F. Hoffmann‐La Roche Ltd. Basel Switzerland

8. Division of Medical Oncology Department of Medicine Kansas University Cancer Center Kansas City Kansas USA

9. Division of Hematology/Oncology Department of Medicine Tisch Cancer Institute Mount Sinai Hospital New York New York USA

10. University Medical Center Mainz Mainz Germany

11. Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases) Faculty of Medicine Freiburg University Medical Center University of Freiburg Freiburg Germany

12. University of Freiburg Signalling Research Centres BIOSS and CIBSS Freiburg Germany

13. German Cancer Consortium (DKTK), partner site Freiburg Germany

14. Hannover Medical School Hannover Germany

15. Division of Gastroenterology & Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria

16. Division of Gastroenterology and Hepatology Department of Medicine Taipei Veterans General Hospital Taipei Taiwan

17. Institute of Clinical Medicine School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan

18. Division of Hematology/Oncology East Carolina University Greenville North Carolina USA

19. Medical Oncology/TSET Phase 1 Program Stephenson Cancer Center University of Oklahoma Norman Oklahoma USA

20. Medical Oncology and Hematology Unit Humanitas Cancer Center IRCCS Humanitas Research Hospital Rozzano Milan Italy

21. Division of Oncology Department of Translational Medicine University of Piemonte Orientale Novara Italy

Funder

NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

European Association for the Study of the Liver

Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg

Wellcome Trust

Associazione Italiana per la Ricerca sul Cancro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32468

Reference37 articles.

1. Hepatocellular carcinoma

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications;Cancers;2024-08-19

2. Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma;Oncology;2024-07-30

3. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma;J TRANSL INTERN MED;2024

4. Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study;European Journal of Gastroenterology & Hepatology;2024-07-26

5. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment;Hepatology;2024-07-19